Literature DB >> 27052360

Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension.

Carlo Marini1,2, Bruno Formichi3,4, Carolina Bauleo3, Claudio Michelassi4, Edoardo Airò3, Giuseppe Rossi5, Carlo Giuntini6.   

Abstract

In chronic heart failure (CHF) due to systemic cardiovascular disease, obese patients have better survival. Bodyweight versus survival was analyzed post hoc in subjects with limited scleroderma (SSc) and isolated pulmonary artery hypertension (PAH), i.e. with CHF due to pulmonary vascular disease. Rheumatologists referred scleroderma subjects for evaluation, and PAH was ascertained by right heart catheterization (RHC). Forty-nine SSc-PAH subjects were stratified by body mass index (BMI): obese 7 (14.3 %), overweight 11 (22.4 %), normal weight 21 (42.9 %), and underweight 10 (20.4 %) for 24-month follow-up and pooled together for long-term 72-month follow-up. Survival was analyzed by Kaplan-Meier method. Multivariate Cox proportional hazards modeling helped to assess variables associated to survival. At 24 months (17 events), survival increases with BMI across four groups (logrank for trend P = 0.031). By Cox multivariate mortality, best model included: BMI (P = 0.043), low lung diffusion (DLco, P = 0.007), and reduced stroke volume index (SVI, P = 0.017). At 72 month (37 events), higher BMI values were associated with better survival but not significantly (P = 0.076). By multivariate modeling BMI did not enter any model, whereas low DLco entered all (P < 0.001). Also low SVI (P = 0.02) and low mixed venous saturation (SvO2, P = 0.009) were associated with the prognosis. From PAH diagnosis to final event, BMI had small (5.4 %), but significant decline (P < 0.001). This is ascribed to CHF progression, and may explain BMI predictive power weakening. The results suggest BMI decline should be contrasted, DLco is useful for screening and with SVI and SvO2 for assessing prognosis and treatment.

Entities:  

Keywords:  Bodyweight; Lung diffusion; Pulmonary hypertension; Scleroderma; Survival

Mesh:

Year:  2016        PMID: 27052360     DOI: 10.1007/s11739-016-1446-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  29 in total

1.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.

Authors:  Micah R Fisher; Stephen C Mathai; Hunter C Champion; Reda E Girgis; Traci Housten-Harris; Laura Hummers; Jerry A Krishnan; Fredrick Wigley; Paul M Hassoun
Journal:  Arthritis Rheum       Date:  2006-09

2.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

3.  Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function.

Authors:  Finn Gustafsson; Charlotte B Kragelund; Christian Torp-Pedersen; Marie Seibaek; Hans Burchardt; Dilek Akkan; Jens Jakob Thune; Lars Køber
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

4.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

5.  Improved survival in limited scleroderma-related pulmonary artery hypertension.

Authors:  Carlo Marini; Bruno Formichi; Carolina Bauleo; Claudio Michelassi; Roberta Pancani; Renato Prediletto; Massimo Miniati; Giosuè Catapano; Simonetta Monti; Francesca Mannucci; Antonio Tavoni; Anna D'Ascanio; Luigi Emilio Pastormerlo; Alberto Giannoni; Carlo Giuntini
Journal:  Intern Emerg Med       Date:  2013-01-30       Impact factor: 3.397

6.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.

Authors:  Stefan D Anker; Abdissa Negassa; Andrew J S Coats; Rizwan Afzal; Philip A Poole-Wilson; Jay N Cohn; Salim Yusuf
Journal:  Lancet       Date:  2003-03-29       Impact factor: 79.321

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.

Authors:  Steven M Kawut; Darren B Taichman; Christine L Archer-Chicko; Harold I Palevsky; Stephen E Kimmel
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

9.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04

10.  The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox".

Authors:  Barak Zafrir; Yochai Adir; Waseem Shehadeh; Michal Shteinberg; Nabia Salman; Offer Amir
Journal:  Respir Med       Date:  2012-11-28       Impact factor: 3.415

View more
  3 in total

1.  Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension.

Authors:  Lacedonia Donato; Carpagnano Giovanna Elisiana; Galgano Giuseppe; Schino Pietro; Correale Michele; Natale Daniele Brunetti; Ventura Valentina; Di Biase Matteo; Foschino Barbaro Maria Pia
Journal:  Intern Emerg Med       Date:  2016-11-25       Impact factor: 3.397

2.  The Association of Body Mass Index With Mortality Among Pulmonary Hypertension Patients: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Chaoxin Jiang; Xiongde Fang; Wenjin Fu
Journal:  Front Public Health       Date:  2022-05-10

Review 3.  Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.

Authors:  James M Gwinnutt; Maud Wieczorek; Giulio Cavalli; Andra Balanescu; Heike A Bischoff-Ferrari; Annelies Boonen; Savia de Souza; Annette de Thurah; Thomas E Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja Stamm; Karen Walker-Bone; Joep Welling; Mirjana I Zlatković-Švenda; Francis Guillemin; Suzanne M M Verstappen
Journal:  RMD Open       Date:  2022-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.